Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227370 · ClinicalTrials.gov registry record · Phase 3
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT00227370 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 136 participants.
The verdict
NCT00227370, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
The study evaluated the efficacy and safety of a prolonged, continuous course of Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir, the standard of care upon initiation of the study, to 12 months of Valganciclovir.
Interventions
- OTHER Placebo
- DRUG valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2003-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00227370
The ClinicalTrials.gov registry entry for NCT00227370 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00227370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00227370 about?
NCT00227370 is a clinical study titled "Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation". The study evaluated the efficacy and safety of a prolonged, continuous course of Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir, the standard of care upon initiation of the study, to 12 months of Valganciclovir.
What is the current status of trial NCT00227370?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2003-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00227370?
The interventions under investigation include: Placebo (OTHER), valganciclovir (DRUG).
Who is sponsoring clinical trial NCT00227370?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.